Hopp til innhold
NHI.no
Annonse

Nyreskaden

Innhold i artikkelen

Andelen av pasientene med diabetes som utvikler nefropati (nyreskade) er avtagende, sannsynligvis på grunn av bedre kontroll av blodsukkeret. 

Nyreskaden skyldes at diabetessykdommen med årene medfører endringer i nyrene. Små blodårer blir trangere, og de delene av nyrene som filtrerer ut urinen (glomeruli og nefroner) blir forandret og fungerer dårligere. Den nedsatte nyrefunksjonen medfører økt utskillelse av proteinet albumin i urinen, noe vi altså kan påvise ved en enkel undersøkelse av urinen. Nyreskaden ved diabetes øker med varigheten av diabetes, men dårlig regulert diabetes er en vel så viktig faktor. Også arvelige faktorer spiller inn. Høyt blodtrykk, røyking, høye kolesterolverdier og sammensetningen av kosten er medvirkende risikofaktorer.

Annonse

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Diabetisk nefropati . Referanselisten for dette dokumentet vises nedenfor

  1. Helsedirektoratet. Nasjonal faglig retningslinje for diabetes. Oslo; Helsedirektoratet, sist faglig oppdatert desember 2018. helsedirektoratet.no
  2. Åsberg A, Reisæter A, et al. Norsk Nyreregister. Årsrapport 2021. Nettside besøkt 13.03.23. www.kvalitetsregistre.no
  3. Valmadrid CT, Klein R, Moss SE, Klein BE: The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160: 1093-1100. PubMed
  4. Persson F, Rossing P. Nyresygdom ved type 2-diabetes. Ugeskr Læger 2012; 174: 2150. Ugeskrift for Læger
  5. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, Binder C, Parving HH: Predictors of the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 2004; 328: 1105-8. British Medical Journal
  6. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-32. PubMed
  7. Caramori ML, Fioretto P, Mauer M: The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 2000; 49: 1399-1408. PubMed
  8. Caramori ML, Kim Y, Huang C, Fish AJ, Rich SS, Miller ME, Russell G, Mauer M: Cellular basis of diabetic nephropathy. 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes 2002; 51: 506-13. PubMed
  9. Solini A, Dalla Vestra M, Saller A, Nosadini R, Crepaldi G, Fioretto P: The angiotensin-converting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes. Diabetes 2002; 51: 251-5. PubMed
  10. Rudberg S, Rasmussen LM, Bangstad HJ, Osterby R: Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria. Diabetes Care 2000; 23: 544-8. PubMed
  11. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-9. British Medical Journal
  12. The Microalbuminuria Collaborative Study Group: Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven-year prospective study. Diabet Med 1999; 16: 918-25. PubMed
  13. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12. British Medical Journal
  14. The Diabetes Control and Complications Trial Research: Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Group. Diabetes 1997; 46: 1829-39. PubMed
  15. Chaturvedi N, Fuller JH, Taskinen MR: Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care 2001; 24: 2071-7. PubMed
  16. Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, Burgess E, Hille DA, Dickson TZ, Shahinfar S, Brenner BM: Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003; 26: 1402-7. PubMed
  17. Hovind P, Rossing P, Tarnow L, Parving HH: Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2003; 26: 911-6. PubMed
  18. Mollsten AV, Dahlquist GG, Stattin EL, Rudberg S: Higher intakes of fish protein are related to a lower risk of microalbuminuria in young Swedish type 1 diabetic patients. Diabetes Care 2001; 24: 805-10. PubMed
  19. Murussi M, Baglio P, Gross JL, Silveiro SP: Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up study. Diabetes Care 2002; 25: 1101-3. PubMed
  20. Stevens LA, Schmid CH, Greene T, et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2 Am J Kidney Dis 2010;56: 486-95 10.1053/j.ajkd.2010.03.026
  21. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G: Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004; 27: 195-200. PubMed
  22. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-47. Annals of Internal Medicine
  23. Nosadini R, Velussi M, Brocco E, et al. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 2000; 49: 476-84. PubMed
  24. Wong TY, Choi PC, Szeto CC, To KF, Tang NL, Chan AW, Li PK, Lai FM: Renal outcome in type 2 diabetic patients with or without coexisting nondiabetic nephropathies. Diabetes Care 2002; 25: 900-5. PubMed
  25. Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: A clinical practice guideline. BMJ 2021 May 11; 373:n1091. PMID: 33975892 PubMed
Annonse
Annonse